Gan & Lee Pharmaceuticals Co., Ltd.

Develops, produces and markets insulin analogues and their associated delivery devices. Its portfolio lists insulin lispro, insulin glargine, the lispro 25R premix, insulin aspart and injection pens, with ongoing development in GLP-1 receptor agonists and weekly insulin. Founded in 1998, it operates a 200,000-square-metre park in Beijing and a base in Linyi.